Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Investor's Business Daily on MSN17h
Amgen Shrugs Off A Surprise Setback For One Of Its Obesity DrugsAmgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback